Patient characteristics
| . | HIV+ . | HIV+ treated . | ||
|---|---|---|---|---|
| P . | SLP . | IR . | PIR . | |
| No. | 11 | 12 | 14 | 12 |
| Age, y | 38 (23-50) | 36 (19-49) | 41.5 (20-51) | 43.5 (32-57) |
| VL, log copies/mL | 4.66 (4.04-6.27) | 4.9 (4.48-5.45) | 1.70 (1.70-2.70) | 1.70 (1.70-2.64) |
| CD4, cells/μL | 210 (50-254) | 535 (380-970) | 630 (210-1130) | 121 (46-277) |
| CD8, cells/μL | 654 (390-870) | 991 (560-2098) | 918 (380-2347) | 842 (253-1540) |
| Time after first HIV+, mo | 21 (14-36) | 41 (14-178) | — | — |
| Time after Tx, mo | — | — | 22 (7-66) | 24 (5-80) |
| Time follow-up | NA | 55 (19-221) | 41 (12-70) | 65 (33-111) |
| CD4 at follow-up | NA | 482 (380-975) | 672 (371-1055) | 260 (75-470) |
| CD4 change,* cells/y | −151 (−433 to −117) | 19 (−57 to 78) | 230 (132 to 923) | 32 (−7 to 90) |
| . | HIV+ . | HIV+ treated . | ||
|---|---|---|---|---|
| P . | SLP . | IR . | PIR . | |
| No. | 11 | 12 | 14 | 12 |
| Age, y | 38 (23-50) | 36 (19-49) | 41.5 (20-51) | 43.5 (32-57) |
| VL, log copies/mL | 4.66 (4.04-6.27) | 4.9 (4.48-5.45) | 1.70 (1.70-2.70) | 1.70 (1.70-2.64) |
| CD4, cells/μL | 210 (50-254) | 535 (380-970) | 630 (210-1130) | 121 (46-277) |
| CD8, cells/μL | 654 (390-870) | 991 (560-2098) | 918 (380-2347) | 842 (253-1540) |
| Time after first HIV+, mo | 21 (14-36) | 41 (14-178) | — | — |
| Time after Tx, mo | — | — | 22 (7-66) | 24 (5-80) |
| Time follow-up | NA | 55 (19-221) | 41 (12-70) | 65 (33-111) |
| CD4 at follow-up | NA | 482 (380-975) | 672 (371-1055) | 260 (75-470) |
| CD4 change,* cells/y | −151 (−433 to −117) | 19 (−57 to 78) | 230 (132 to 923) | 32 (−7 to 90) |
VL indicates viral load; Tx, treatment; —, not applicable because not treated at sampling time; NA, not applicable because of beginning of treatment.
CD4 changes are calculated differently for the 4 groups of patients: P was calculated from first seropositivity to sampling time (14-36 months); SLP was calculated from first seropositivity to follow-up time (19-221 months); IR was calculated from the initiation of treatment to the first time point of the plateau phase of CD4 gain (12-70 months); PIR was calculated during the follow-up period (33-111 months).